Identifies molecular signatures linked to disability and clinical outcomes in multiple sclerosis, suggesting new insights into disease pathways.
To identify shared blood-based molecular signatures linking serum metabolomics and proteomics with clinical disability, patient-reported outcomes, and neuroimaging markers in multiple sclerosis (MS), providing mechanistic insight into pathways underlying disease severity.
No takes yet. Share an insight, caveat, or question.
Siavoshi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: